Op-Eds
Patients vs. Paternalism
Decisions about drug safety and efficacy are far from easy. Tysabri, a multiple sclerosis (MS) drug that was voluntarily withdrawn from the market last year…
Op-Eds
No Beef in Meat Packaging Controversy
Yet another potential food scare is being manufactured out of thin air — or rather out of carbon monoxide. Last November, with little fanfare,…
Op-Eds
The Lancet Pricks Itself
The term “medical journals” elicits automatic respect from most people. Not from me: I read them. I've found the editors to be increasingly…
Op-Eds
Is CSR A-OK?
A Friday conference at the American Enterprise Institute will try to answer the question: "Is Corporate Social Responsibility (CSR) Serious Business?" And not…
Op-Eds
The Ideas Marketplace — Sans Market?
WASHINGTON—The Jack Abramoff scandal has many individual players, but it’s also added fuel to an older and broader theme—the quest to purge politics of money.
Op-Eds
U.S. tech: Get to China
We once scorned the idea the Internet could be censored. Many politicians have tried to stop porn, but always to no avail. Spam still…